Search for: [Abstract = "Introduction\: Cutaneous lupus erythematosus \(CLE\) is a group of clinically diverse autoimmune diseases, primarily affecting the skin and mucosa, with complex and not fully understood pathogenetic mechanisms. Toll\-like receptors \(TLRs\) belong to the main class of pattern recognition receptors \(PRRs\) of the innate immune response. They are involved in recognition of pathogenic microorganisms. In addition, Toll\-like receptors initiate intracellular signaling cascades leading, inter alia, to translocation of the nuclear NF\-κB molecule, which is a key transcription factor promoting the expression of genes encoding immune response molecules. Hydroxychloroquine is the first line of treatment for cutaneous lupus erythematosus \(SCLE and DLE\) when topical therapy is insufficient. However, not all patients achieve clinical remission of skin lesions. One of the postulated mechanisms of action of antimalarial drugs is inhibition of signaling pathways dependent on type 7 and 9 endosomal TLRs. Moreover, current scientific reports show the role of type 7, 8 and 9 TLRs in the pathogenesis of systemic lupus erythematosus. Their function in the development of cutaneous lupus erythematosus is not fully explained and is currently under investigation. Taking into account the above reports, the analysis of TLR receptor expression in skin biopsies in patients with subacute and discoid forms of lupus"]
